Targeting of anti-tumor responses with bispecific antibodies

D. M. Segal, J. H. Qian, D. Mezzanzanica, M. A. Garrido, J. A. Titus, S. M. Andrew, A. J T George, C. R. Jost, P. Perez, J. R. Wunderlich

Research output: Contribution to journalArticlepeer-review


T cells can be induced to specifically lyse tumor cells with bispecific antibodies containing anti-T cell receptor mAbs crosslinked to anti-tumor mAbs. Such targeted cytolysis requires that the target cell be bound directly to the cytotoxic cell. In addition, targeted T cells mediate a second activity, the secretion of factors that can block the growth of both tumor target cells and bystander tumor cells. When given to nude mice bearing intraperitoneal human ovarian carcinoma, targeted human T cells cause the rapid removal of most tumor cells from the peritoneum, and markedly prolong the times of survival of treated mice. The efficacy of targeted T cells for treating human cancer is currently being tested in clinical trials.

Original languageEnglish
Pages (from-to)390-402
Number of pages13
Issue number2-4
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'Targeting of anti-tumor responses with bispecific antibodies'. Together they form a unique fingerprint.

Cite this